Amrubicin: Difference between revisions

	WikiDoc Resources for Amrubicin
Articles
Most recent articles on Amrubicin Most cited articles on Amrubicin Review articles on Amrubicin Articles on Amrubicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Amrubicin Images of Amrubicin Photos of Amrubicin Podcasts & MP3s on Amrubicin Videos on Amrubicin
Evidence Based Medicine
Cochrane Collaboration on Amrubicin Bandolier on Amrubicin TRIP on Amrubicin
Clinical Trials
Ongoing Trials on Amrubicin at Clinical Trials.gov Trial results on Amrubicin Clinical Trials on Amrubicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Amrubicin NICE Guidance on Amrubicin NHS PRODIGY Guidance FDA on Amrubicin CDC on Amrubicin
Books
Books on Amrubicin
News
Amrubicin in the news Be alerted to news on Amrubicin News trends on Amrubicin
Commentary
Blogs on Amrubicin
Definitions
Definitions of Amrubicin
Patient Resources / Community
Patient resources on Amrubicin Discussion groups on Amrubicin Patient Handouts on Amrubicin Directions to Hospitals Treating Amrubicin Risk calculators and risk factors for Amrubicin
Healthcare Provider Resources
Symptoms of Amrubicin Causes & Risk Factors for Amrubicin Diagnostic studies for Amrubicin Treatment of Amrubicin
Continuing Medical Education (CME)
CME Programs on Amrubicin
International
Amrubicin en Espanol Amrubicin en Francais
Business
Amrubicin in the Marketplace Patents on Amrubicin
Experimental / Informatics
List of terms related to Amrubicin

Amrubicin
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
ATC code	L01DB10 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (7S,9S)-9-Acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;
CAS Number	110267-81-7 ;
PubChem CID	178149;
ChemSpider	2299344 ;
UNII	93N13LB4Z2;
KEGG	D08854 ;
ChEMBL	ChEMBL1186894 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C25H25NO9
Molar mass	483.46 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@](C(=O)C)(N)C[C@@H]5O[C@@H]4OC[C@@H](O)[C@@H](O)C4;
	InChI InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1 ; Key:VJZITPJGSQKZMX-XDPRQOKASA-N ;
(what is this?) (verify)

← Older edit

Latest revision as of 17:36, 18 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.^[1] It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.^[2]

Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.^[3] ^[4]

It has also been studied for the treatment of bladder carcinoma^[5] and gastric cancer.^[6]

References

↑ Ueoka H, Ohnoshi T, Kimura I (November 1992). "[New anthracycline analogues in the treatment of lung cancer]". Gan To Kagaku Ryoho (in Japanese). 19 (13): 2146–9. PMID 1332624.
↑ Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)" (PDF). Retrieved 2008-08-17. ^{[dead link]}
↑ Celgene Corporation (2008). "Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". Retrieved 2009-07-10.
↑ Medical News Today (2007). "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer". Retrieved 2009-07-10.
↑ Ohmori H, Tsushima T, Kobashi K (April 1996). "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]". Gan To Kagaku Ryoho (in Japanese). 23 (5): 601–6. PMID 8678519.
↑ Tsushima K, Sakata Y, Munakata A; et al. (June 1991). "[A phase II study of SM-5887 for advanced gastric cancer]". Gan To Kagaku Ryoho (in Japanese). 18 (7): 1151–4. PMID 1647150.

[pmid1332624-1] Ueoka H, Ohnoshi T, Kimura I (November 1992). "[New anthracycline analogues in the treatment of lung cancer]". Gan To Kagaku Ryoho (in Japanese). 19 (13): 2146–9. PMID 1332624.

[/SUMITO17-2] Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)" (PDF). Retrieved 2008-08-17. ^{[dead link]}

[Celgene_Biopharmaceutical-3] Celgene Corporation (2008). "Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". Retrieved 2009-07-10.

[Medical_News_Today-4] Medical News Today (2007). "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer". Retrieved 2009-07-10.

[pmid8678519-5] Ohmori H, Tsushima T, Kobashi K (April 1996). "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]". Gan To Kagaku Ryoho (in Japanese). 23 (5): 601–6. PMID 8678519.

[pmid1647150-6] Tsushima K, Sakata Y, Munakata A; et al. (June 1991). "[A phase II study of SM-5887 for advanced gastric cancer]". Gan To Kagaku Ryoho (in Japanese). 18 (7): 1151–4. PMID 1647150.

[1]

[2]

[3]

[4]

[5]

[6]

v t e Chemotherapeutic agents/Antineoplastic agents (L01)
Alkylating and alkylating-like agents	Nitrogen mustards: (Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Bendamustine, Uramustine) Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin) Platinum (alkylating-like): (Carboplatin, Cisplatin, Oxaliplatin, Triplatin tetranitrate, Satraplatin) Alkyl sulfonates:(Busulfan, Treosulfan) Hydrazines:(Procarbazine, Dacarbazine, Temozolomide) Aziridines:(ThioTEPA)
Antimetabolites	Folic acid: (Aminopterin, Methotrexate, Pemetrexed, Raltitrexed). Purine:(Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine) Pyrimidine:(Capecitabine, Cytarabine, Decitabine, Fluorouracil, Floxuridine, Gemcitabine)
Spindle poison/mitotic inhibitor	Taxane: (Docetaxel, Larotaxel, Paclitaxel). Vinca: (Vinblastine, Vincristine, Vindesine, Vinorelbine).
Cytotoxic/antitumor antibiotics	Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Pixantrone, Valrubicin) streptomyces (Actinomycin, Bleomycin, Mitomycin, Plicamycin) - Hydroxyurea
Topoisomerase inhibitors	Camptotheca: (Camptothecin, Topotecan, Irinotecan, Rubitecan), Podophyllum:(Etoposide, Teniposide)
CI monoclonal antibodies	Receptor tyrosine kinase (Cetuximab, Panitumumab, Trastuzumab) - CD20 (Rituximab, Tositumomab) - other (Alemtuzumab, Bevacizumab, Gemtuzumab)
Photosensitizers	Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin
Tyrosine kinase inhibitors	Axitinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, Vandetanib
Cyclin-dependent kinase inhibitor	Seliciclib
Other	retinoids (Alitretinoin, Tretinoin), Fusion protein (Aflibercept) - Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase (Pegaspargase), Bexarotene, Bortezomib, Celecoxib, Denileukin diftitox, Elesclomol, Estramustine, Irofulven, Ixabepilone, Masoprocol, Mitotane, Oblimersen, Testolactone, Tipifarnib, Trabectedin

Revision as of 15:53, 9 April 2015 view source Turky Alkathery (talk \| contribs) CMEUser, nocaptcha, Administrators 6,562 edits No edit summary ← Older edit	Latest revision as of 17:36, 18 August 2015 view source WikiBot (talk \| contribs) Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators 57,550 edits m Protected "Amrubicin": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
(No difference)

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	L01DB10 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (7S,9S)-9-Acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
CAS Number	110267-81-7^N
PubChem CID	178149
ChemSpider	2299344^Y
UNII	93N13LB4Z2
KEGG	D08854^Y
ChEMBL	ChEMBL1186894^N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₅H₂₅NO₉
Molar mass	483.46 g/mol
3D model (JSmol)	Interactive image
SMILES O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@](C(=O)C)(N)C[C@@H]5O[C@@H]4OC[C@@H](O)[C@@H](O)C4
InChI InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1^Y Key:VJZITPJGSQKZMX-XDPRQOKASA-N^Y
^NY (what is this?) (verify)

Amrubicin: Difference between revisions

Latest revision as of 17:36, 18 August 2015

Overview

References

Navigation menu

Search